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SIGNIFICANCE
Atopic dermatitis is the most common inflammatory skin 
condition globally that affects both children and adults. The 
symptoms of atopic dermatitis as well as the demands of 
treatment often contribute to a significant impact on pa-
tient quality of life (QoL). This QoL impairment may also 
extend to caregivers, partners and close family members 
of atopic dermatitis sufferers. This review aims to evaluate 
the impact of atopic dermatitis on the QoL of patients and 
close relatives. A myriad of tools are available for measur-
ing QoL; a brief description of the most relevant instru-
ments is also presented in this article.
Atopic dermatitis is the most prevalent chronic inflam-
matory skin condition globally. The burden of atopic 
dermatitis on children and adults is extensive and 
there is also significant impact on the lives of patient 
caregivers and family members. It is important to be 
able to measure this impact to inform clinical decisions 
and to plan appropriate patient and carer support. The 
current impact of atopic dermatitis on children and 
adults can be measured using several different qua-
lity of life questionnaires: the most frequently used 
are the Dermatology Quality of Life (DLQI), Children’s 
Dermatology Quality of Life and Infants Dermatology 
Quality of Life. The impact on partners and family can 
be measured using several atopic dermatitis specific 
questionnaires or the Family DLQI or the generic Fa-
mily Reported Outcome Measure, FROM-16.
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The dry, itchy, eczematous skin of atopic dermati-tis (AD) has a profound impact on quality of life 
(QoL). The pathophysiology of AD is postulated to be 
a combination of epithelial barrier defects, (1) immune 
system dysfunction (2) and psycho-neurogenic inflam-
mation (3). The characteristics of AD are heterogenous 
with varying clinical presentations according to age or 
anatomical region (4). AD has also been described as a 
systemic disorder given its wide-ranging associations 
from malignancies to cardiovascular effects (5). It is 
the most prevalent chronic inflammatory skin condition 
globally (6), but there are challenges in collating the 
extensive epidemiological data. Worldwide, up to 50% 
of cases labelled as AD are not in fact truly ‘atopic’ i.e. 
phenotypic eczema that is associated with circulating 
allergen-specific IgE. A phase two study of the largest 
AD sample in the world demonstrated a weak association 
between flexural eczema and atopy (7, 8) and therefore it 
cannot be assumed this presentation is always attributable 
to atopy. Furthermore ad hoc prevalence studies are often 
diverse and based on different diagnostic and sampling 
methods making true data comparison difficult.
The burden of disease of AD on children is extensive 
and there is also significant impact on the lives of patient 
caregivers and family members (9). In affected adults, 
this effect is multi-dimensional with implications for 
mental health, work productivity and QoL. This review 
focusses on the measurement of QoL in AD patients, in 
particular on the QoL measures recommended by Har-
monising Outcome Measures for Eczema (HOME), and 
the implications of the wider impact that AD has across 
different ages, social groups and countries.
Health-related quality of life (HRQoL) is a specific 
aspect of the wider concept of “quality of life”. Throug-
hout this manuscript “quality of life” refers to HRQoL.
EPIDEMIOLOGY OF ATOPIC DERMATITIS
The determination of accurate prevalence data for any 
disease depends on there being clear agreed diagnostic 
criteria and the ability to gather data from subjects that 
represent the general population. However, there are 
several differing diagnostic criteria that may be used in 
surveys of AD prevalence, contributing to confusion, and 
the methodology of many surveys leads to selection bias, 
for example if data from a clinic is measured rather than 
from a population cross-section. The various prevalence 
figures quoted in this review relate to the population 
described in the corresponding reference and may not 
be generalised to other populations.
Most AD epidemiological data have focussed on the 
paediatric population (9). The advent of the International 
Study of Asthma and Allergies in Children (ISAAC) 
has provided a standardised platform to identify over a 
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million children suffering with AD worldwide (10). The 
prevalence ranged from 0.9% (India) to 22.5% (Ecuador) 
in a sample of 380,000 children aged 6–7 years from 
60 countries (11). For teenagers (ages 13–14, 660,000 
subjects) the prevalence values range from 0.2% (China) 
to 24.6% (Columbia) with generally higher values seen 
in Latin America and Africa. In the European Union the 
point prevalence is 4.4% (12).
There have been several studies examining the adult 
population. The European Community Respiratory 
Health Survey (ECRHS) study collated data from US 
and European subjects and identified prevalence rates 
ranging from 0.3% (Switzerland) to 6.2% (Estonia) (13). 
Recently, Barbarot et al. (12) conducted an international 
survey on representative samples of adults (ages 18–64) 
worldwide using standardised methods and diagnostic 
criteria. Prevalence values ranged from 2.1% (Japan) 
to 8.1% (Italy), and there were further variations within 
countries and regions. Generally, there was a higher pre-
valence in females, but in the UK and the USA there was 
no significant difference in prevalence between females 
and males. Peak prevalence was from age 25 to 45 years, 
with AD then becoming less prevalent with increasing 
age (p <0.05). However, a study limitation was that sub-
jects self-diagnosed using modified UK Working Party 
criteria, with under 10% having a physician diagnosis. 
Regardless of which measure was used, USA subjects 
reported having the most severe AD, whereas in southern 
Europe the prevalence of mild disease was higher than 
in northern countries such as in the UK (12).
A systematic review of 13 studies conducted in the 
Netherlands and the UK demonstrated that the prevalence 
of AD assessed by general practitioners (1.8–9.5%) was 
lower than when self-reported (11.4–24.2%) (14). This 
may be because milder cases do not present to general 
practitioners, or self-reporting may over-diagnose. Kim 
et al. (15) analysed 110,000 cases and reported that the 
mean age of AD diagnosis was 1.6 years, with < 5% cases 
experiencing persistent disease at 20 years follow-up. 
Disease severity, duration, later onset and female sex 
were all associated with persistent disease.
As the above studies demonstrate, there is a large 
burden of disease from AD. It is imperative to measure 
the impact of this condition in those who are affected 
by it, because this information is essential to inform 
the clinician concerning choice of therapy. This data is 
also useful in the assessment of novel therapies, and in 
monitoring response to therapy.
PATIENT REPORTED OUTCOME MEASURES
A Patient Reported Outcome (PRO) is any report that co-
mes directly from a patient about a health condition or its 
treatment, without interpretation by a clinician or anyone 
else (16). The initial drive for PROs was led by the phar-
maceutical industry. In the US during the late 1980s there 
was an increased awareness of the importance of patient 
input in assessing treatment. The seminal Rand Health 
Insurance experiment collected patients’ self-report of 
health status to understand the impact of health insurance 
plans on health outcomes (17). Following this, Tarlov et 
al. (18) conducted an observational study to ascertain how 
outcomes of care were affected by specific components 
of the health care system. This landmark Medical Outco-
mes Study concluded that tools should be developed for 
“monitoring the patient wellbeing in office practice and 
clinical research.” The Food and Drug Administration 
(FDA) initiated the requirement for QoL assessments 
in oncology trials (19). However, a report of a PRO 
measure used as an endpoint in a clinical trial involved 
anti-hypertensives: when the results were published by the 
press, although the endpoint measured tolerability rather 
than efficacy, the stock market value of the pharmaceu-
tical company rose resulting in an economic impact of a 
health related outcome (20). The term “patient reported 
outcome” was coined in the year 2000 and the plethora 
of outcome measures subsequently developed led to the 
development of a PRO harmonisation group (21).
PROs may include evaluation of symptoms, functional 
status, or general or HRQoL.
THE IMPACT OF ATOPIC DERMATITIS ON 
QUALITY OF LIFE 
QoL measurement has become an integral aspect of 
monitoring disease and intervention efficacy across 
dermatology. Three dimensions in particular have been 
proposed that are key to QoL evaluation: ‘now’, ‘long-
term’ and ‘family’ (22). The ‘now’ is important for current 
assessment, but the long-term effects as well as wider 
implications for family should also influence treatment 
and health-economic decisions. It is vital to understand 
the various aspects of QoL impairment across the range 
of AD sufferers.
The impact of AD on children is comparable to other 
childhood chronic diseases such as cerebral palsy, epi-
lepsy and cystic fibrosis (23). A review by Olsen et al. 
(24) identified data from 37 studies on 4082 children with 
AD and found that AD had, on average, a moderate effect 
on health-related QoL. However in each study there was 
a wide range of reported impacts of AD. Children with 
AD are often affected on a daily basis including problems 
when feeding, changing clothes and playing, thus depri-
ving them of a ‘normal childhood’(25). The chronicity 
of AD is often not a focus in studies: QoL scores may 
differ between primary and secondary care settings as 
the latter are likely to include more severe cases.
There are similar concerns for teens and adolescents. 
Parents fear that their children may be unable to make 
friends when older (26). Growing up, they develop a 
sense of being different due to alienating comments and 
having to explain several misconceptions (27), eventually 
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leading to a feeling of isolation and the need to be ‘dif-
ferent’ (28). Despite the debilitating nature of AD and the 
wider effect on school-work, AD does not impact aca-
demic performance in adolescents (29) and compliance 
with topical treatment in this group was reported in one 
study to be as high as 96% (30). Nevertheless, AD may 
influence career pathways. Advice to adolescents about 
work where having AD may involve risk is important to 
help them decide appropriate careers (31). The transition 
from paediatric to adult clinics is often a challenging 
period and the Department of Health in England has 
identified a specialised need in this area (32). A trial of 
‘young adult’ clinics for AD patients with open access 
psychological support demonstrated significant impro-
vement in QoL with high satisfaction rates.
AD has long been considered mainly a childhood pro-
blem, but the prevalence in adults ranges between 3–5% 
(33). In a review of two cohorts, 38% of adults with AD 
had symptom onset in childhood. (34). Over half of adult 
patients report that AD has a moderate to extremely large 
effect on their QoL. Many describe pain, stinging and 
embarrassment from their AD impacting their choice of 
clothing. The burden increases with increasing severity 
of disease (35): 57% of adults miss at least one day of 
work in the preceding year and describe problems with 
intimacy and feelings of guilt due to AD. Over 10% of 
1189 people with moderate to severe AD demonstrated 
depressive symptoms (35). Of those subjects suffering 
from severe AD, 88% felt their ability to tackle life was 
at least partly compromised (35).
Whether the patient is a child, teenager or adult, AD 
impacts on the extended family as well as on caregi-
vers, a concept described as ‘The Greater Patient’ (36). 
This effect may be experienced by anyone with a close 
relationship with the patient (37). This broader impact 
of disease is increasingly being recognised as another 
dimension of healthcare, with the advent of several new 
questionnaires to ascertain this impact. AD, being a com-
mon childhood condition, is a particularly relevant field 
of research given the ‘web of relationships’ involved 
from an early stage (38). 
Several major life changing decisions, such as choice 
of education, choice of career, choice of partner or deci-
sions about whether to have children may be influenced 
by having a chronic skin disease such as AD (39). The 
impact of the disease on such decisions can therefore 
alter the life course of people affected, with the impact 
of the disease echoing through the decades.
A BRIEF HISTORY OF QOL IN ATOPIC 
DERMATITIS
A plethora of QoL measures have been developed within 
dermatology, especially in psoriasis and AD. A systematic 
review by Rehal & Armstrong (40) in 2011 attempted to 
identify trends in outcome instruments used in AD trials. 
Of the 382 studies included, only 67 studies incorporated 
QoL measurements. Eleven instruments were identified 
for measuring QoL, of which the Children’s Dermatology 
Quality of Life (CDLQI) was the most frequently used 
followed by Dermatitis Family Index (DFI), Dermatology 
Life Quality Index (DLQI) and Infant Dermatology Qua-
lity of Life questionnaire (IDQoL). Three tools measured 
the QoL of family members of patients with AD: DFI, 
Parents Index of Quality of Life in Atopic Dermatitis 
(PIQol-AD) and Parents of Children with Atopic Der-
matitis (PQol-AD). The authors surmised that an overall 
increase in use of QoL instruments from 1985 to 2010 
indicated the emerging importance of QoL measures for 
patient evaluation and management. 
HARMONISING OUTCOME MEASURES FOR 
ATOPIC DERMATITIS
Noting the myriad of outcome assessments for AD, the 
first International Conference on HOME was held in 
2010 (41) and a decision was made for a core outcome set 
(COS) to be developed for AD. All scales had to pass the 
OMERACT filter of truth, discrimination and feasibility 
(42). The studies assessing the validity of different instru-
ments were required to pass the COSMIN checklist (43). 
In 2011, 4 outcome domains were agreed on: symptoms, 
clinical signs, long-term control of flares and QoL (44). 
At the HOME III meeting Eczema Area and Severity 
Index (EASI ) was recommended as the instrument for 
the outcome disease severity (45), HOME IV recom-
mended Patient Oriented Eczema Measure (POEM) as 
the PRO for measuring symptoms (46). Heinl et al. (47) 
in 2016 conducted a study on QoL instruments used in 
eczema trials using the Global Resource of Eczema Trials 
(GREAT) database. In the 303 studies included from 
2002–2014, approximately 90% of studies used a PRO, 
however only 63 used QoL measures. Eighteen named 
and 4 unnamed QOL instruments were found. Unlike 
the study by Rehal et al. mentioned above, (40), Heinl et 
al. (47) did not find evidence of increasing use of QOL 
measures, however confirming Rehal et al’s finding, the 
DLQI, CDLQI, IDQol and DFI were the most frequently 
used instruments. Four instruments measured the impact 
of AD on carers of patients of which two were named 
(DFI, PIQoL-AD). 
Around the same time Hill et al. (48) conducted a 
systematic review looking at trends in disease severity 
and QoL instruments for patients with AD. Only 45 of 
the 135 identified studies measured QoL. Again, the 
DLQI, CDLQI, IDQoL and DFI were the most commonly 
used instruments. Hill et al. found 28 QoL measures in 
contrast to the 22 reported by Heinl and colleagues (47), 
possibly due to the different databases searched. Hill et 
al. (48) also found that the number of articles reporting 
on QoL peaked in 2012. Three instruments (DFI, FDLQI 
and PIQoL-AD) measured impact of QoL on caregivers. 
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HOME V concentrated on the definition core outcome 
for long-term control and its measurement as well as future 
areas of research for a tool to measure children’s QoL (49). 
It was agreed that a new instrument should be developed 
for long-term control and that further research on itch 
intensity was necessary. It was also decided that none of 
the QoL instruments could be recommended at that point 
in time due to concerns with validation in certain areas.
However, the sheer number of QoL instruments in 
the above studies, with some instruments used only in 
single studies, highlighted the importance of standardised 
methods for measuring QoL in AD in order to compare 
various intervention measures. Therefore, at the 2019 
HOME VII meeting (50) it was agreed to recommend 
DLQI and CDLQI to measure the QoL of adults and 
children and the proxy measure IDQoL to measure the 
QoL of infants. Two new instruments which had been de-
veloped in response to the recommendations from HOME 
V, Atopic Dermatitis Control Test (ADAPT) and Recap 
of Atopic Eczema (RECAP) were recommended for 
measuring long-term control. In addition, the Numerical 
Rating Scale (NRS-11) (51) to measure the intensity of 
itch was recommended in addition to POEM as the PRO 
to measure symptoms. It was also agreed that the COS 
for AD should be measured at baseline and end of the 
primary endpoint to ensure comparability in trial results. 
QUALITY OF LIFE INSTRUMENTS FOR ATOPIC 
DERMATITIS CHOSEN BY THE HOME INITIATIVE
Historically, the value of clinical research has been 
reduced by different outcome measures being used in 
individual studies, making comparison impossible. The 
HOME initiative, by identifying a set of core measures 
provides the potential for improved assessment, compa-
rison and combination of data.
Dermatology Life Quality Index 
The DLQI is a dermatology-specific questionnaire deve-
loped in 1994 (52). There are over 110 translations, used 
in over 80 countries (53). The DLQI is quick and easy to 
perform and score in routine clinical practice. During the 
initial development, 120 patients answered the open-ended 
question “list all the ways your skin disease affects you”. 
The questionnaire was developed from the answers. 
The DLQI is a 10-item questionnaire with a one 
week recall period. It is completed, on average, in two 
minutes. The DLQI assesses the impact of skin disease 
on symptoms and feelings, daily activities, leisure, work 
and school, personal relationships and the impact of 
treatment. The ten question scores (each 0–3) are added 
to give the DLQI score (maximum 30). 
The DLQI has been extensively validated in numerous 
studies with regards to its psychometric properties as well 
as its use in clinical research (54–56). The DLQI struc-
ture has been examined with respects to dimensionality 
indicating one to 4 factors across various studies (54). 
It is responsive to change (57, 58) with high test–retest 
reliability (59, 60). 
The DLQI validated score banding (61) allows mea-
ningful score interpretation. For example, score band 0–1 
indicates no effect on a patient’s life and 11–20 a large ef-
fect. This banding can help inform clinical decisions. The 
DLQI has been significantly correlated with numerous 
other measures highlighting its construct validity (54), 
and used as the standard comparator in the validation 
of many novel QoL questionnaires. The DLQI has been 
mapped to the EQ-5D using ordinal logistic regression 
allowing the prediction of dermatology-specific utility 
values from generic EQ-5D scores (62). The model al-
lows the capture of disease-specific data that generic 
measures are often unable to capture, thereby generating 
more precise health economic data without the need for 
utilising multiple questionnaires. However, though the 
model is validated for large groups of data, it requires 
further testing at an individual subject level. An electro-
nic format has been developed and validated against the 
paper format demonstrating equivalence (63).
Although the DLQI is the most commonly used measure 
across dermatology (55, 64), several limitations have been 
described including concerns regarding under-representa-
tion of emotional aspects and its uni-dimensionality (65). 
Furthermore, there are concerns over score interpretation 
when “not relevant” options are chosen. In the DLQI, for 
8 of the 10 items it is possible for the respondent to choose 
“Not relevant”. If the subject does this for one question, 
because the life aspect enquired about is not part of the 
respondent’s usual life pattern, then the overall maximum 
score is reduced. The more questions that are answered 
“not relevant” the greater the impact on the maximum 
possible score. Some subjects might therefore not reach a 
critical level that is used to help inform a clinician concer-
ning the use of some therapy, even though the reason that a 
question may be “not relevant” may be that the skin disease 
has severely impacted that aspect of the respondent’s life. 
It has therefore been suggested that the final score should 
be adjusted depending on the number of “Not relevant” 
answers given (66).
However, introducing an additional more complicated 
scoring system may not be appropriate (67) and would be 
impractical in busy clinics, require a wide range of reva-
lidation studies to be performed and introduce confusion 
into the interpretation of DLQI scores (68). Whatever 
method is used to calculate them, DLQI scores should 
be used to help the clinician take the most appropriate 
decision for individual patients, and not used to restrict 
clinical judgement. A simple approach would be for any 
clinician reviewing a completed DLQI, or indeed any 
QoL questionnaire, to note whether or not there were any 
“Not relevant” answers, to enquire further and to take 
this into account as part of the information informing 
their clinical decisions.
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Although many properties of the DLQI have been ex-
tensively validated, the DLQI has been criticised for not 
having been subject to Rasch analysis (69, 70), a method 
for the refinement of items and to convert the ordinal scale 
to a fundamental measure. However, the high face validity 
of the questions, the simplicity of its use and the easy in-
terpretability of its scores have led to the DLQI being the 
first QoL measure with which dermatologists worldwide 
have become familiar (71), contributing to a cultural shift 
towards patient-centred medicine. Many clinicians have 
embedded the use of the DLQI in their routine practice 
because of their experience of its usefulness in routine 
clinical care, and the DLQI is incorporated in national 
guidelines or registries in at least 40 countries.
The DLQI has been recommended by the HOME ini-
tiative as the core instrument for measuring the impact 
of AD on the QoL of adult patients with AD (50).
Minimal Clinically Important Difference 
The minimal clinically important difference (MCID) is 
the minimal change in score considered clinically signi-
ficant by clinicians and patients (72). This provides ad-
ditional meaning to QoL score changes. The DLQI MCID 
value is 4 points (73). We have proposed a ‘multiple-
MCID’ concept has (74) to allow a more distinguishing 
analysis of interventional studies. However, this requires 
extensive further validation.
Children’s Dermatology Life Quality Index
The CDLQI measures the impact of skin conditions on 
the QoL of children aged 4–16 years (75). A 10-item 
questionnaire was developed, based on 169 replies from 
children, asking how their skin condition affected their 
life. The CDLQI measures impact over the last week 
on symptoms and feelings, leisure, school or holidays, 
personal relationships, sleep and treatment. One question 
has a choice of two options dependent on whether or not 
within the last week the child was in school or on holiday. 
Each question has 4 possible answers. A cartoon version 
appeals to younger children (76). The CDLQI has been 
validated extensively (77–79). It is completed in mean in 
2 min and has score bands to give meaning to the scores 
(80). There is no published minimal clinically important 
difference (MCID) for CDLQI described for use across 
all skin diseases. However, for use in children with AD 
it has been suggested that the MCID for the CDLQI is 
between 6–8 points (81).
 The CDLQI has been recommended by HOME as the 
core QoL instrument for measuring the impact of AD on 
the QoL of children (50). 
Infants’ Dermatitis Quality of Life index
The IDQoL is a dermatitis specific parent/caregiver proxy 
measure of the QoL of children under the age of 4 years 
(82). It is a 10-item questionnaire with a one week recall 
period. The items measure the perceived impact on QoL 
of itch and scratch, mood, time to sleep, playing or swim-
ming, family activities, mealtimes, treatment, dressing and 
undressing, and bath time. An additional question records 
the severity of dermatitis as perceived by the parent/care-
giver. The IDQoL had been translated into several langu-
ages and is frequently used in AD trials and validation 
aspects have been described (83). The IDQoL has been 
recommended by HOME as the core QoL instrument for 
measuring the impact of AD on the QoL of infants (50). 
The core measures chosen may change in the future if 
more appropriate measures are developed, but there is huge 
strength to be gained by always using the same set. The mi-
nimal clinically important difference and descriptive score 
meaning bands have not been described for the IDQoL. 
Disability adjusted life years
Whereas Quality Adjusted Life Years (QALYs) are years 
of healthy life lived, Disability Adjusted Life Years 
(DALYs) are years of healthy life lost. To calculate the 
burden of a certain disease, the disability weighting is 
multiplied by the number of years lived in that health 
state and is added to the number of years lost due to that 
disease (84). Using DALYs, the global burden of skin 
disease survey revealed that eczema causes the highest 
burden of all skin diseases worldwide (85). Eczema is 
one of top 50 most common causes of disease, with a 
global prevalence estimated at 229 million people af-
fected. However, it must be remembered that AD affects 
the QoL of not only those directly affected but also their 
close family members. 
FAMILY IMPACT OF ATOPIC DERMATITIS 
Impact on parents
AD is a chronic disease so the symptoms require constant 
attention. Treatment for AD includes regular use of emol-
lients along with various topical and systemic measures. 
The treatment process can have an adverse impact on 
the QoL of the patient (86) and also the main caregivers, 
especially when young children are affected. Inevitably 
parents are affected too. A meta-ethnography study (87) 
collated parental and childhood/adolescent experiences 
of AD. It is postulated that parent and child bonding is 
affected as skin irritation may limit physical interactions 
(88). Furthermore, the associated behavioural difficulties 
such as restlessness and hyperactivity may be demanding 
for parents, resulting in frustration and exhaustion (89). 
Parents may choose not to have further children because 
of the current burden on the wider family. Dedicating time 
for treatment application and extra housework also direct-
ly impacts parental work responsibilities and therefore has 
financial implications (90). The symptoms experienced 
by children e.g. sleep disturbance, restlessness, psycho-
logical strain and embarrassment may all be experienced 
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second hand by parents and therefore their QoL is a key 
determinant of the child’s well-being (26, 91).
Parents report having to apply creams that children dis-
like, often resulting in the need for coercion (92). Cultural 
issues may play an important role in parental attitudes to 
their affected child. Mothers may feel they did something 
wrong during pregnancy, or develop a sense of guilt for 
neglecting other children because of their focus on the 
child with AD (91). Anxiety may be exacerbated by con-
flicting advice on management, including the long-term 
sequelae of topical corticosteroids being inadequately 
explained by health professionals (93). 
Loss of sleep is another familiar theme in parents of 
children with AD. Angelhoff et al. (94) conducted a study 
into the perceptions of sleep in such parents. Eleven 
mothers and one father, with children aged 0–2 years with 
SCORing Atopic Dermatitis (SCORADs) of  > 15 were 
interviewed. All but one parent experienced fragmented 
sleep. Most parents accepted the sleep loss but expressed 
a desire for longer uninterrupted sleep. Sleep loss led 
to fatigue with parents perceiving this had a negative 
effect on the whole family. The participants felt that the 
sleep loss was normalised by other family members and 
ignored by health professionals. The participants also 
felt that dynamics between parents and other siblings 
had changed, leading to feelings of guilt and sadness. 
Moore et al. (95) reported that parents of children 
with eczema suffered sleep loss, with the mothers losing 
a median of 39 min and fathers a median of 45 min of 
sleep. In contrast, parents of children with asthma lost 
no sleep. While both parents of children with AD had 
increased anxiety scores, the mothers had two-fold hig-
her scores of depression than mothers of children with 
asthma. This was related more to the sleep loss than to 
a direct effect of the eczema.
In contrast, in an ongoing large prospective, longitudi-
nal, population-based cohort study 11,649 mother–child 
pairs in the UK were followed up by Ramirez et al. (96) 
from birth to 10 years. Children were classified as having 
AD on the basis of the presence of flexural dermatitis 
on two occasions. After adjusting for confounders, sleep 
duration and early morning awakening were similar in 
mothers of children with active AD and mothers with 
children never having reported AD. However, difficulty 
in falling asleep, subjectively insufficient sleep and 
day-time exhaustion were more frequently reported in 
mothers of children with active AD. The authors also 
reported larger effects in mothers of children with more 
severe AD. Adjusting for child sleep disturbances did 
not change the conclusions, and other factors such as 
anxiety and stress related to caring for children with AD 
may have been contributory.
Pustisek et al. (97) studied the QoL of 171 parents 
(mean age 32 years) of children with AD in Croatia. The 
mean FDLQI score (range 0–30) was 13.6 ± 6.0. indicating 
a major effect on the QoL of parents. The most frequently 
recorded problems were time spent looking after the 
child, household expenditure and emotional distress, as 
in a Ukraine study (98). The mean Perceived Stress Scale 
score was 20.0 ± 5.8, 7 points higher than the average per-
son aged 30–40 years, indicating higher stress levels in 
parents of children with AD and a correlation with QoL. 
The impact of a child’s eczema on the QoL of mothers 
and fathers may vary. Marciniak et al. (99) assessing pa-
rents QoL with the FDLQI, found that children’s AD had 
a greater impact on the QoL of mothers than of fathers. 
Whilst the impact on the social life, spare time and daily 
expenditure was similar, mothers’ relationships with 
other people were more affected than fathers’ relations-
hips with others, however the greatest impact on fathers 
was on their work or education. This was in contrast to 
the study by Pustisek et al. (97) where work or education 
were the lowest scoring items on the FDLQI: this could 
be because most participants in Pustisek’s study were 
female with over half on maternity leave or unemployed.
Counter-intuitively, there may be positive outcomes 
resulting from a child suffering with AD. Parents may 
develop a strengthened bond with their children through 
the extra time spent treating and supervising them (100). 
To stop children from scratching, parents spend more 
time holding children closer, and balanced with the 
discomfort of physical symptoms, this overall creates 
a deeper emotional closeness (26). Parents also feel 
empowered by learning about AD and educating others 
about this debilitating condition (87).
Impact on siblings
Basra & Finlay proposed the term “Greater Patient’ to 
encompass the interdependence of patients with their 
close relations (36). In childhood AD this includes the 
parents, who are generally the caregivers, however, in 
childhood siblings usually live together and their lives 
may also be affected. Whilst there are many studies 
on the QoL of siblings of children affected with other 
medical conditions, notably cancers (101–106), there is 
a lack of information on the impact of QoL on siblings 
of children affected with skin conditions, including AD. 
It is difficult to compare from the literature the effect on 
the QoL of siblings of skin disease compared to other 
diseases, due to the wide variety of instruments that have 
been used. Siblings of children with chronic conditions 
may have the same QoL as their peers (107), but it has 
also been suggested that siblings may have increased 
levels of distress (102). The parent child relationship 
and the sibling bond may also be affected when a child 
in the family has a chronic condition (108).
These negative interactions with family members (94, 
99) coupled with sleep deprivation can leave patients, 
and their carers, feeling exhausted, stressed and depres-
sed (96, 97). There may therefore be repercussions on 
siblings of patients affected with AD: this area needs 
further investigation.
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The above findings illustrate the importance of asses-
sing the QoL of family members. Several dermatology 
specific and AD specific validated instruments exist for 
measuring the impact of QoL on family members of 
patients with AD. The HOME initiative has not yet add-
ressed this. However, the TREatment of ATopic eczema 
(TREAT) Registry Taskforce has recommended that for 
research registries for paediatric and adult patients with 
AD, if family impact is measured, the Family Dermato-
logy Life Quality Index (FDLQI) should be used (109).
QUALITY OF LIFE INSTRUMENTS FOR FAMILY 
MEMBERS
Family Dermatology Life Quality Index
The FDLQI is a 10-item questionnaire, with a recall 
period of one month, assessing the impact on the QoL 
of adult family members of people of any age with any 
skin condition (110). The questionnaire includes the do-
mains of emotional and physical wellbeing, relationships, 
leisure activities, social life, burden of care, impact on 
job/study, housework and expenditure. Each question is 
scored on a 4-point scale (0–3). The FDLQI has been 
translated into several languages (111) and has been used 
in various studies involving AD and other dermatological 
conditions (97, 99, 112–116). 
Dermatitis Family Index
The DFI, the first family QoL questionnaire in derma-
tology measures the impact of having a child with AD 
on the QoL on their adult family members (117). This 
10-item dermatitis specific questionnaire measures 
the impact over the last week on QoL in the domains 
of housework, food preparation and feeding, sleep of 
others in the family, family leisure activities, time spent 
on shopping, expenditure, tiredness, emotional distress, 
relationships and impact of child’s treatment. Each ques-
tion is scored from 0–3 points. There are no validated 
banding descriptors for the DFI, but some studies have 
used non-validated scoring descriptors (118, 119). The 
DFI has the advantage of being eczema specific and its 
measurement properties have been reviewed (120). The 
DFI, along with DLQI, CDLQI and IDQoL is one of the 
most frequently used instruments for measuring QoL in 
eczema studies (40, 47, 121).
Parents Index of QoL in Atopic Dermatitis
The PIQoL-AD is another AD specific measure to as-
sess the impact of the child’s AD on the QoL of parents 
(122). Developed on the basis of multinational qualitative 
interviews with parents of children up to age 8 years with 
AD, this is a 28-item unidimensional questionnaire (123). 
The lower the score, the better the QoL, a change of 2–3 
PIQoL-AD points over time is considered meaningful.
Childhood Atopic Dermatitis Impact Scale (CADIS)
CADIS is a QoL measure for parents of children with 
AD combined with a proxy measure for children under 
the age of 6 years (124). It measures the impact on QoL 
of the domains of symptoms, activity limitations and 
behaviour, family and social function, parent sleep and 
parent emotion. This 45-item questionnaire uses 5-point 
Likert Scales giving a maximum score of 180. The recall 
period is the last 4 weeks and the questionnaire can be 
completed in approximately 6 min (125). Whilst it does 
not have score band descriptors, the MCID is considered 
to be a 12% change from the total score or a 12% change 
from any of the individual domains (126).
Family Reported Outcome Measure
Speciality and condition specific questionnaires cannot 
compare the impact on QoL of family members between 
different specialities. Golics et al. (127) developed the 
Family Reported Outcome Measure (FROM-16), based 
on relatives of patients from 26 medical specialties.
FROM-16 has 16 questions and can be used to assess 
the QoL of any adult member of the family of a patient of 
any age with any disease. The average completion time 
is 2 min. FROM-16 consists of the Emotional domain 
with 6 questions and the Personal and Social Life do-
main with 10 questions. Each question has three possible 
answers: ‘Not at all’, ‘A little’ and ‘A lot’ scoring 0, 1 
and 2, respectively. Validation studies have been com-
pleted in Germany and Thailand and further validation 
characteristics are being studied. FROM-16 can be used 
to compare the QoL of family members across different 
disciplines in medicine, thus making it easier to make 
meaningful comparisons in QoL trials involving different 
medical conditions. 
The Impact on Family Scale (IOF) (128, 129) has been 
validated to measure the impact of QoL on the adult fa-
mily members of children suffering with chronic illness 
or disability. However, unlike the FROM-16, which can 
be used in the family members of patients of any age, 
the IOF should only be used for family members of af-
fected children
DISCUSSION
In any scientific endeavour, it is essential to be able to 
measure some characteristic of what is being studied. 
Without measurement, it may be possible to describe, but 
impossible to make meaningful comparisons or detect 
change. It could almost be said that if you can’t measure 
something, it doesn’t really exist, at least to a scientist. 
The same applies in medicine, a field of science that co-
exists as an ‘art’. Advances have followed the ability to 
measure: measuring blood pressure has enabled identi-
fication and control of hypertension, measuring visual 
fields has allowed diagnosis of ophthalmic and neurolo-
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gical conditions and measuring frequency of micturition 
is used as an alert to diabetes and prostatic hypertrophy. 
Perhaps because of the visual nature of dermatology, a 
focus on measurement came late to our subject. But this 
delayed focus has coincided with a realisation that, as part 
of delivering the highest quality of care, we need to better 
understand what our patients are experiencing (130). In 
addition, qualitative studies should be used more often 
in combination with quantitative studies to gain more 
insight into the real burden of diseases such as AD.
This review has focussed on questionnaires specifically 
designed to measure the impact on QoL of skin diseases 
in general or of AD in particular. However, there are 
also a wide range of questionnaires that are designed to 
be used across all diseases. Examples of such measures 
include the Short-Form 36, the WHOQOL and EuroQoL 
(EQ-5D). Utility information giving QALY information 
is typically calculated from EQ-5D data, and this is 
sometimes used by national or international drug regu-
lation agencies to inform decisions concerning resource 
allocation. However, use of QoL data in this way may 
overlook critical aspects of the reality of the impacts 
of skin diseases, such as the psychological impact that 
understanding the risk of mortality, say of a malignant 
melanoma, may have. And having a basal cell carcinoma 
that is treated appropriately may have a low impact on 
QoL, but if untreated the long-term consequences can be 
extremely serious. Therefore, when QoL measures are 
used to inform resource allocation, wider aspects of the 
conditions must also be considered.
This review has described some of the many ways in 
which the lives of people with AD are affected by their 
condition. Large multicentre studies in Europe and the 
USA determined that patients with psoriasis felt that their 
dermatologists were not aggressive enough with therapy: 
it is likely that the same applies at least to adult AD. By 
having insight into the individual patient’s experience, 
more appropriate therapeutic decisions may be made, 
especially over the coming decade with the advent of 
many novel powerful systemic therapies for AD.
The Greater Patient, the close family members, may all 
experience impact on their QoL through having a family 
member with AD. But the “Greater Patient” also acts as 
the “Greater Therapist”, as family members support the 
patient with practical therapeutic help, such as application 
of topical emollients and drugs, and giving encouragement 
to persist with therapy. The role of the family in promoting 
adherence to agreed treatment plans should not be unde-
restimated. Therefore, understanding the experiences of 
family members, and identifying their needs may make a 
crucial contribution to the success of therapy.
Being able to measure the QoL impact of AD provi-
des stark challenges to the health care team. Of course, 
the over-riding aim must be to effectively suppress the 
disease. Having identified the QoL problems we can no 
longer ignore them and we are obliged to creatively de-
velop methods to address these issues. We now have the 
tools to assess prospectively the impact of AD on QoL.
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